Federal solicitation · 75A50126C00001 · back to recent
Strategic Marburg Advanced Research and Development, Preparedness, Registration, Evaluation and Procurement (SMART-PREP)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF · NAICS 541714 · NONE · $1,042.1M est.
Likely incumbent
AVITA MEDICAL AMERICAS, LLC
on contract 75A50126C00003
Heuristic partial prefix match. Total value $25.5M. Awarded 2026-04-06. Agency: Department of Health and Human Services.
Prefix-match heuristic; treat as a strong lead, not a confirmed fact.
Solicitation description
This acquisition will allow BARDA to invest Project BioShield funds for the advanced development, US Food and Drug Administration (FDA) licensure, procurement, shipping, and vendor managed inventory (VMI) storage of MARV monovalent vaccine. This contract was awarded on a hybrid cost reiumbursement/fixed price basis as circumstances do not allow the agency to define its requirements sufficiently to allow for a fixed-price type contract.
Similar opportunities
Other open SAM.gov opportunities under the same NAICS, prioritizing the same buying agency.
| Title | Agency | Est. value | Basis |
|---|---|---|---|
| Biomedical Advanced Research and Development Authority... | HEALTH AND HUMAN... | $99.7M | same agency naics |
| R & D to develop Execabase to combat S. aureus | HEALTH AND HUMAN... | $86.8M | same agency naics |
| BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003) | HEALTH AND HUMAN... | $7.5M | same agency naics |
| Toxicity of Resin 3-D Printing Emissions: Phase 1 | HEALTH AND HUMAN... | - | same agency naics |
| BIOmolecular Grammar for protein Aggregation Modulation... | HEALTH AND HUMAN... | - | same agency naics |
| Infinium EPIC v2 Methylation Kits | HEALTH AND HUMAN... | - | same agency naics |
| Intent to Sole Source - Tapestri Single-Cell DNA +... | HEALTH AND HUMAN... | - | same agency naics |
| PAXGENE Ribonucleic acid extraction, quality?control?and... | HEALTH AND HUMAN... | - | same agency naics |
Data this profile does NOT cover
- No FPDSAward rows for NAICS 541714 in the trailing 12 months; vendor concentration unavailable.